ライフサイエンスコーパス: antidiabetic

1 idepressants, heart failure medications, and antidiabetics.

2 r, these findings implicate the brain in the antidiabetic action of systemic FGF19 and establish the

3 improved antioxidant, antidyslipidemic, and antidiabetic action that may serve as a potential therap

4 necessary nor sufficient to explain leptin's antidiabetic action.

5 ma glucocorticoid levels is required for its antidiabetic action.

6 ute to its capacity to lower insulinemia and antidiabetic action.

7 esis, 17beta-estradiol (estradiol) manifests antidiabetic actions in humans and rodents.

8 To investigate the potential antidiabetic actions of FGF21 in insulin-deficient Gcgr(

9 il a key role for the brain in mediating the antidiabetic actions of leptin in the context of T1D.

10 We evaluated the role and antidiabetic actions of the ERbeta selective agonist WAY

11 ole-body insulin action and in mediating the antidiabetic actions of TZDs.

12 op improved PPARgamma modulators that retain antidiabetic actions while minimizing untoward effects.

13 potential leptin sensitizer with additional antidiabetic actions.

14 e present study deals with the evaluation of antidiabetic activities of Fagioli di Sarconi beans (Pha

15 In this study, we assessed the potential antidiabetic activities of NRTN relative to liraglutide,

16 ts suggest a role for FGF21 in mediating the antidiabetic activities of PPARgamma agonists.

17 he paradoxes among their agonistic function, antidiabetic activities, and side effects and should all

18 ents are widely consumed for their purported antidiabetic activities.

19 ave been synthesized and evaluated for their antidiabetic activity in sucrose-challenged low-dosed st

20 , namely, compound 29, has demonstrated oral antidiabetic activity in the ob/ob mouse model, the diet

21 lts strongly support the hypothesis that the antidiabetic activity of Cr(III) and the carcinogenicity

22 ingly, the novel proposed mechanisms for the antidiabetic activity of PPARgamma agonists, consisting

23 mic activities were also prepared, and their antidiabetic activity results indicate its association m

24 44%, while it was further evaluated for its antidiabetic activity using a type 2 diabetes experiment

25 eover, one such compound, SR1664, has potent antidiabetic activity while not causing the fluid retent

26 cholinesterase activity but presented strong antidiabetic activity, in the order: 'Arbequina' approxi

27 ry, we have identified a small molecule with antidiabetic activity, providing a tool for exploring is

28 s of different benzothiazoles with potential antidiabetic activity.

29 Here, we show that both the antidiabetic agent metformin and insulin phosphorylate t

30 that incorporate a structural moiety of the antidiabetic agent succinobucol.

31 Metformin is a first-line antidiabetic agent taken by 150 million people across th

32 and inhibition assays for canagliflozin, an antidiabetic agent verified its effective binding to bot

33 NAADP is thus a potential antidiabetic agent with therapeutic relevance.

34 ngiotensin-converting enzyme inhibitor, oral antidiabetic agent, calcium, and vitamin D.

35 TNFRI combined with the antidiabetic agent, metformin, improved DBD beyond that

36 ptidyl peptidase-4 inhibitor sitagliptin, an antidiabetic agent, which lowers blood glucose levels, a

37 ntroquinonol indicate that it is a potential antidiabetic agent.

38 ium, which is a proposed insulin mimetic and antidiabetic agent.

39 e, I discuss a rational basis for the use of antidiabetic agents as novel and potentially effective t

40 t group) or short-acting insulin and/or oral antidiabetic agents for blood glucose >/=180-250 mg/dl (

41 y of such vanadium coordination complexes as antidiabetic agents is described.

42 mediate-acting insulin analogues) with other antidiabetic agents is urgently required to guide approp

43 PPARgamma agonists are antidiabetic agents known to suppress inflammatory macro

44 T2D patients are routinely treated with oral antidiabetic agents such as sulfonylureas or dipeptidyl

45 ly, the same pathway is activated by certain antidiabetic agents such as thiazolidinediones.

46 s devoid of the side effects of the marketed antidiabetic agents thiazolidinediones and the dual agon

47 y mass index, use of insulin, and other oral antidiabetic agents).

48 g, and prostate cancer and use of TZD, other antidiabetic agents, and insulin were identified.

49 enosine, glucose-insulin-potassium, statins, antidiabetic agents, FX06, iron chelation, and ranolazin

50 r-gamma (PPARgamma) agonists, a new class of antidiabetic agents, have been shown to possess antiinfl

51 Metabolic stress, as well as several antidiabetic agents, increases hepatic nucleotide monoph

52 Compared with noninsulin antidiabetic agents, premixed insulin analogues were mor

53 In an effort to identify new antidiabetic agents, we have discovered a novel family o

54 hypoglycemia, and can be combined with other antidiabetic agents.

55 eed the in vitro activity of known synthetic antidiabetic agents.

56 ent, whereas 7 (28%) of 25 controls required antidiabetic agents.

57 receptor pharmacology that may lead to novel antidiabetic agents.

58 long-acting insulin analogues and noninsulin antidiabetic agents.

59 ery and design of GK activators as potential antidiabetic agents.

60 ctivators represent a potential new class of antidiabetic agents.

61 e oil (EVOO) to combat several diseases, the antidiabetic and anti-cholinesterase activity of Spanish

62 oxy fatty acids (FAHFAs), lipids with potent antidiabetic and anti-inflammatory activities, indicates

63 ed class of endogenous mammalian lipids with antidiabetic and anti-inflammatory effects.

64 The antidiabetic and antiatherosclerotic effects of adiponec

65 macrophages (MacT3) to analyze its potential antidiabetic and antiatherosclerotic effects.

66 11 might play important roles in metformin's antidiabetic and anticancer effects.

67 wo congeners 70 and 90 exhibiting consistent antidiabetic and antidyslipidemic activities were also p

68 The intervention comprised withdrawal of antidiabetic and antihypertensive drugs, total diet repl

69 onectin is an adipocyte-derived hormone with antidiabetic and antiinflammatory actions.

70 iabetic obese patients with pioglitazone, an antidiabetic and antiinflammatory PPARgamma agonist, res

71 tin system is necessary for the CNS-mediated antidiabetic and cardiovascular actions of leptin, chron

72 werful central nervous system (CNS)-mediated antidiabetic and cardiovascular actions.

73 onectin is an adipocyte-derived hormone with antidiabetic and insulin-sensitizing properties.

74 Both the antidiabetic and lipotropic effects are lost in liver-sp

75 ogenic acid (a polyphenol) and metformin (an antidiabetic and possible longevity promoting drug).

76 roblast growth factor 21 (FGF21) is a potent antidiabetic and triglyceride-lowering hormone whose hep

77 ting drugs, such as estrogen-like compounds, antidiabetics and sirolimus/rapamycin.

78 lopram (an antidepressant), troglitazone (an antidiabetic), and enilconazole (a fungicide).

79 pic adipokine that exerts anti-inflammatory, antidiabetic, and antiatherogenic effects through its re

80 fects, such as anticancer, hepatoprotective, antidiabetic, anti-inflammatory and antibacterial activi

81 Adiponectin is an adipocyte-derived, antidiabetic, antiatherogenic adipocytokine that is pres

82 eted by adipocytes, has insulin-sensitizing, antidiabetic, antiinflammatory, and antiangiogenic prope

83 ological effects, among them, antimicrobial, antidiabetic, antioxidative, antiobesity and antihyperte

84 of carbasugar SGLT2 inhibitors as potential antidiabetic/antitumor agents.

85 reatment with AMPK activators, including the antidiabetic biguanide metformin, inhibited FXR agonist

86 they reduced use of heart failure drugs and antidiabetics by 12.9% and 13.4%, respectively.

87 (SGLT-2) inhibitors have emerged as a novel antidiabetic class of drugs that exert favourable result

88 ation for the large-scale manufacture of the antidiabetic compound sitagliptin.

89 if effective delivery of potentially active antidiabetic compound such a the organic vanadate peptid

90 ing evidence that thiazolidinediones (TZDs), antidiabetic compounds that are synthetic ligands for th

91 samples obtained from patients treated with antidiabetic doses of metformin.

92 many bioactive natural products, such as the antidiabetic drug acarbose, the crop protectant validamy

93 Metformin (Met) is an approved antidiabetic drug currently being explored for repurposi

94 ch, it represents a target for anticancer or antidiabetic drug development.

95 agon-like peptide 1 (GLP-1) receptor via the antidiabetic drug exenatide led to improvements in both

96 The antidiabetic drug metformin (which is derived from an he

97 Treatment with the antidiabetic drug metformin during ovariectomy-induced w

98 The antidiabetic drug metformin exhibits both chemopreventiv

99 The effect of the antidiabetic drug metformin on tumor growth was investig

100 ment of pregnant p53d/d mice with either the antidiabetic drug metformin or the antioxidant resveratr

101 that activation of AMPK with the widely used antidiabetic drug metformin or with the AMP mimetic 5-am

102 genous TAK1 was activated by oligomycin, the antidiabetic drug metformin, 5-aminoimidazole-4-carboxam

103 nefits of exercise and is the target for the antidiabetic drug metformin.

104 , and AMPK is the target for the widely used antidiabetic drug metformin.

105 n detail the effects of the most widely used antidiabetic drug metformin.

106 ffective utilization of E. maxima as an oral antidiabetic drug or functional food ingredient with a p

107 We further show that the antidiabetic drug phenformin, which activates AMP kinase

108 debated for several years as to whether the antidiabetic drug pioglitazone increases the risk for bl

109 Binding of the thiazolidinedione antidiabetic drug pioglitazone led to the discovery of a

110 d ( approximately 10-fold) treatment, or the antidiabetic drug rosiglitazone, all known PPAR activato

111 Glyburide (GLB) is an antidiabetic drug routinely used to treat gestational di

112 key intermediate in the preparation of oral antidiabetic drug Saxagliptin is discussed with an empha

113 Explorations of apoA-I as a novel antidiabetic drug should extend to treatments of diabeti

114 Metformin is a widely used antidiabetic drug that exerts cardiovascular protective

115 eneration biguanide, is a commonly used oral antidiabetic drug that has been shown recently to stimul

116 r3 O(OCOEt)6 (OH2 )3 ](+) (A), a prospective antidiabetic drug that undergoes similar H2 O2 induced o

117 ntiation following exposure to BDE-47 or the antidiabetic drug troglitazone (TROG).

118 armful consequence of this widely prescribed antidiabetic drug when used as a monotherapy in elderly

119 Metformin is the first-line antidiabetic drug with over 100 million users worldwide,

120 l-tolerated and Federal Drug Agency-approved antidiabetic drug, has positive effects on insulin resis

121 e, Lehraiki et al. report that metformin, an antidiabetic drug, inhibited melanogenesis, in vitro and

122 e first time demonstrate a novel role of the antidiabetic drug, metformin, in suppressing uveitis in

123 lization and lectin analysis of acarbose, an antidiabetic drug, to dabsyl-tagged enzyme substrates to

124 tformin is the most commonly prescribed oral antidiabetic drug, with well-documented beneficial preve

125 prescribed other diabetes treatments (other antidiabetic drug-exposed group).

126 PD compared to 517 individuals in the other antidiabetic drug-exposed group.

127 for the commercial synthesis of Januvia, an antidiabetic drug.

128 f incretin-based drugs as compared with oral antidiabetic-drug combinations among patients with a his

129 drugs, as compared with those receiving oral antidiabetic-drug combinations, were estimated by means

130 f action is unique in that no other approved antidiabetic drugs act via this mechanism, and raises th

131 ollowing the recent therapeutic successes of antidiabetic drugs aimed at either mimicking GLP-1 or pr

132 relationship between cumulative use of other antidiabetic drugs and either outcome.

133 These data demonstrate that two antidiabetic drugs exert opposite effects on the PepT1 t

134 istration industry guidance for licensing of antidiabetic drugs greatly increased the number of cardi

135 Improved management of antithrombotic and antidiabetic drugs has the potential to reduce hospitali

136 Antidiabetic drugs have been found to have various effec

137 Because currently available antiobesity and antidiabetic drugs have limited efficacy and/or safety c

138 with placebo, subcutaneous insulin, or oral antidiabetic drugs in people with type 1 or type 2 diabe

139 ibitors have been approved as a new class of antidiabetic drugs in type 2 diabetes mellitus, and stud

140 to the carboxylic acid group of the type II antidiabetic drugs nateglinide and meglitinide were synt

141 l/L who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of

142 oup of hybrid nitric oxide-releasing type II antidiabetic drugs possessing a 1-(pyrrolidin-1-yl)diaze

143 This important NR complex is a target for antidiabetic drugs since it binds to DNA and functions a

144 The antidiabetic drugs sitagliptin and exenatide, which inhi

145 Antidiabetic drugs such as peroxisome proliferator-activ

146 rational basis for the development of novel antidiabetic drugs targeting this class of receptors.

147 l can be gradually purged by the glitazones, antidiabetic drugs that are agonists of peroxisome proli

148 lar target of the thiazolidinedione class of antidiabetic drugs that has many side effects.

149 e defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS, when cancer cell

150 r has been further highlighted by reports of antidiabetic drugs treating or promoting cancer.

151 to maximal metformin therapy, all noninsulin antidiabetic drugs were associated with similar HbA(1c)

152 All other antidiabetic drugs were discontinued on admission.

153 e development of GPR119 agonists as new oral antidiabetic drugs will be discussed.

154 approach for the rational design of type II antidiabetic drugs with a reduced risk of contraindicate

155 of any insulin regimen (with or without oral antidiabetic drugs).

156 izes the anticancer drug paclitaxel, certain antidiabetic drugs, and endogenous substrates, including

157 that include the thiazolidinedione class of antidiabetic drugs, as well as derivatives of polyunsatu

158 Moreover, in subjects not taking oral antidiabetic drugs, baseline osteocalcin concentrations

159 s the next generation of insulin-sensitizing antidiabetic drugs, because the currently marketed PPARg

160 receptor for the thiazolidinedione class of antidiabetic drugs, controls mitochondrial network fragm

161 rompted us to investigate the effects of two antidiabetic drugs, rosiglitazone and metformin, on PepT

162 ated with basal insulin with or without oral antidiabetic drugs.

163 e 2 diabetes inadequately controlled on oral antidiabetic drugs.

164 ed remission to a non-diabetic state and off antidiabetic drugs.

165 uately controlled on basal insulin plus oral antidiabetic drugs.

166 d suggest an approach for the development of antidiabetic drugs.

167 merged as a major potential target for novel antidiabetic drugs.

168 rter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs.

169 1)R receptor agonist 2-MeS-ADP, as potential antidiabetic drugs.

170 te effects of the PPARgamma agonist class of antidiabetic drugs.

171 onse to thiazolidinediones (TZDs), which are antidiabetic drugs.

172 lar target of the thiazolidinedione class of antidiabetic drugs.

173 ment include metabolic-modulating agents and antidiabetic drugs.

174 ids and the thiazolidinedione (TZD) class of antidiabetic drugs.

175 get for the thiazolidinedione (TZD) class of antidiabetic drugs.

176 ared with commonly used combinations of oral antidiabetic drugs.

177 ere non-smokers, aged >/=40 years, and using antidiabetic drugs.

178 glycemia through daily dosing of one or more antidiabetic drugs.

179 pment of better and safer PPARgamma-mediated antidiabetic drugs.

180 y disease; however, the mechanism behind its antidiabetic effect has been unclear.

181 This antidiabetic effect is not secondary to weight loss, doe

182 and a number of cellular models to study the antidiabetic effect of ANC, a standardised anthocyanin-r

183 ts glucose production and mediates the early antidiabetic effect of bariatric surgery, and gut microb

184 duction, and both are required for the rapid antidiabetic effect of duodenal jejunal bypass surgery.

185 i.v. glucose tolerance test showed that the antidiabetic effect of i.c.v. FGF19 was solely due to in

186 The antidiabetic effect of leptin has been postulated to occ

187 Thus, the mechanisms responsible for the antidiabetic effect of leptin remain poorly understood.

188 The antidiabetic effect of MTZ does not appear to be a funct

189 this may provide a novel explanation for the antidiabetic effect of this procedure.

190 ly, the search for new compounds with potent antidiabetic effects but fewer undesired effects is an a

191 ed the hypothesis that ranolazine exerts its antidiabetic effects by inhibiting glucagon release via

192 ega-3 fatty acids have anti-inflammatory and antidiabetic effects in humans.

193 19 has previously been shown to exert potent antidiabetic effects in ob/ob mice.

194 and mediates potent insulin sensitizing and antidiabetic effects in vivo by repressing macrophage-in

195 Numerous studies have characterized the antidiabetic effects of adiponectin, yet the precise cel

196 Although the impressive antidiabetic effects of bariatric surgery have been show

197 ulinotropic agents besides GLP mediating the antidiabetic effects of DPP-4 inhibition.

198 Furthermore, the antidiabetic effects of icv leptin administration rapidl

199 tocytes; rather, their data suggest that the antidiabetic effects of metformin in the liver are media

200 sveratrol raises questions about whether the antidiabetic effects of oral resveratrol can act directl

201 tes, but the underlying mechanisms for these antidiabetic effects remain elusive.

202 ng beige/brite cells exhibit antiobesity and antidiabetic effects, nitrate may be an effective means

203 ucrose diet (HFHSD) mice to characterize its antidiabetic effects.

204 sive, anorexic, analgesic, antibacterial and antidiabetic effects.

205 SPPARgammaMs) have been identified that have antidiabetic efficacy and reduced toxicity in preclinica

206 SPPARgammaMs) have been identified that have antidiabetic efficacy comparable with full agonists with

207 FGF1 at a dose one-tenth of that needed for antidiabetic efficacy following peripheral injection ind

208 owth factor (FGF) receptors, we explored the antidiabetic efficacy of centrally administered FGF1, wh

209 ses in an in vivo preclinical model, showing antidiabetic efficacy while exhibiting an improved hemod

210 Despite their proven antidiabetic efficacy, widespread use of peroxisome prol

211 ly, SPPARgammaMs regulated the expression of antidiabetic efficacy-associated genes to a greater exte

212 Ralpha), raising the prospect that estradiol antidiabetic function may be due, in part, to a protecti

213 n experimentally or clinically substantiated antidiabetic functional plant foods and potatoes.

214 nalyses of this novel candidate leanness and antidiabetic gene.

215 or gamma (PPAR) agonist medications, such as antidiabetic glitazone (GTZ) drugs, are neuroprotective

216 diates the vascular protection observed with antidiabetic glitazones.

217 howed efficacy comparable to liraglutide, an antidiabetic GLP-1 analogue that carries a long-chain fa

218 sease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, e

219 There is concern that antidiabetic incretin-based drugs, including dipeptidyl

220 to reduce HCC risk when compared with other antidiabetic interventions.

221 k remains to be done to fully understand the antidiabetic mechanisms of leptin.

222 In this study, we investigated novel antidiabetic MEDICA analogues consisting of methyl-subst

223 ing 784 available human gut metagenomes, how antidiabetic medication confounds these results, and ana

224 ed PC, we examined the effect of duration of antidiabetic medication exposure after PC diagnosis on a

225 Antidiabetic medication exposure was not independently a

226 Antidiabetic medication may modify the incidence of hepa

227 ent diabetes was ascertained based on use of antidiabetic medication or a fasting glucose level of 12

228 s for prediabetes or type 2 diabetes; or (3) antidiabetic medication order.

229 : OR, 0.449; 95% CI, 0.357-0.566), and other antidiabetic medication use (RYGB: OR, 0.747; 95% CI, 0.

230 tes mellitus (30%) based on medical history, antidiabetic medication use, and glycated hemoglobin lev

231 Preoperative use of antidiabetic medication, coupled with an incretin agonis

232 ide 1 (GLP-1) agonist in addition to another antidiabetic medication, during the preoperative period.

233 egation inhibitors, and antihypertensive and antidiabetic medication.

234 outpatient diabetes diagnoses and 1 or more antidiabetic medications (sensitivity, 92.4%; positive p

235 insulin secretagogues, metformin, and other antidiabetic medications among diabetic patients were co

236 f 102 genes in pathways targeted by marketed antidiabetic medications and applied Gene Set Enrichment

237 diabetes and cancer, the effects of various antidiabetic medications on cancer incidence and mortali

238 l and clinical data regarding the effects of antidiabetic medications on cancer incidence and mortali

239 e needed to further elucidate the effects of antidiabetic medications on cancer incidence and progres

240 The use of both lipid-lowering and antidiabetic medications rose in the groups with no or m

241 data on laboratory results and dispensing of antidiabetic medications were extracted from electronic

242 oss, reduction in hemoglobin A1c, and use of antidiabetic medications, and very importantly a lower i

243 (HbA1C) value of 7.4% despite taking 3 oral antidiabetic medications, as well as coexistent hyperten

244 48 mmol/mol) after at least 2 months off all antidiabetic medications, from baseline to 12 months.

245 report that use of insulin, along with other antidiabetic medications, significantly diminished overa

246 uced by both metformin and thiazolidinedione antidiabetic medications.

247 lerance tests, hemoglobin A1C levels, and/or antidiabetic medications.

248 ins and support the idea that pioglitazone's antidiabetic mode of action may, in part, be to inhibit

249 decade-long clinical usage of these drugs as antidiabetics now allows for evaluation of patient-orien

250 Significant reductions in use of antidiabetics occurred in both surgical groups.

251 The antioxidant, anti-inflammatory and antidiabetic potential of fortified cakes were significa

252 These suggest the antidiabetic potential of S. aqueum leaf extract and its

253 The present study evaluates the antidiabetic potential of the flavonoids, rutin and its

254 f their natural or synthetic origin, display antidiabetic properties due to enzyme inhibition (glycog

255 anadium compounds have been reported to have antidiabetic properties for more than a century.

256 The description of the antidiabetic properties of vanadium compounds is describ

257 date, numerous studies have reported on the antidiabetic properties of various plant extracts throug

258 nes), full agonists of PPARgamma with robust antidiabetic properties, which are confounded with signi

259 nthocyanin from maqui berry, and studied its antidiabetic properties.

260 ion, and mounting evidence suggests HDL have antidiabetic properties.

261 ammatory, immunomodulatory, antioxidant, and antidiabetic properties.

262 n T2DM via its putative cardioprotective and antidiabetic property.

263 No antidiabetic regimen has demonstrated the ability to red

264 We aimed to compare the use of different antidiabetic strategies and the incidence of HCC.

265 diovascular outcome of patients treated with antidiabetic sulfonylureas is being considered.

266 ate insulin secretion and are the targets of antidiabetic sulfonylureas.

267 ibition as a potential anti-inflammatory and antidiabetic target in obesity.

268 Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regenera

269 These findings provide a rationale for antidiabetic therapies aimed at lowering serum RBP4 leve

270 ite diagnosis of type 2 diabetes or received antidiabetic therapies during follow-up were classified

271 archically the best when compared with other antidiabetic therapies for the prevention of HCC.

272 Antidiabetic therapies might further improve outcomes in

273 We investigated the effect of antidiabetic therapies on the risk of pancreatic cancer.

274 Gamma (PPARgamma) is a classical target for antidiabetic therapies with thiazolidinedione compounds.

275 oduction and disposal, and a major target of antidiabetic therapies.

276 of the cardiovascular safety profile of new antidiabetic therapies.

277 mising drug leads for both antibacterial and antidiabetic therapies.

278 re development of successful antiobesity and antidiabetic therapies.

279 ell expansion may be key to developing novel antidiabetic therapies.

280 a, or both, were stratified by previous oral antidiabetic therapy and randomly assigned to receive ad

281 ancreas (normoglycemia in the absence of any antidiabetic therapy) survivals were determined, and sev

282 y, dietary habits, physical activity, and/or antidiabetic therapy.

283 Intestinal SGLT1 is a putative target for antidiabetic therapy; however, its physiological regulat

284 receptor gamma (PPARgamma) is the target of antidiabetic thiazolidinedione drugs, which improve insu

285 te differentiation and a canonical target of antidiabetic thiazolidinedione medications.

286 l development and is the molecular target of antidiabetic thiazolidinediones (TZDs), which exert insu

287 ferentiation and target of widely prescribed antidiabetic thiazolidinediones (TZDs).

288 ted with synthetic PPARgamma agonists of the antidiabetic thiazolidinediones class before tBH challen

289 pport the notion that BAT may function as an antidiabetic tissue in humans.

290 BAT) has attracted scientific interest as an antidiabetic tissue owing to its ability to dissipate en

291 n per 1.73 m(2) or higher, and taking stable antidiabetic treatment and ACE inhibitors or ARBs, for a

292 lucose metabolism is an important target for antidiabetic treatment approaches.

293 PARgamma and its pharmacological response to antidiabetic treatment with rosiglitazone.

294 er the oxytocin system a potential target of antidiabetic treatment.

295 ,000 patient years in those prescribed other antidiabetic treatments (IRR 0.72, 95% confidence interv

296 Antidiabetic treatments aiming to reduce body weight are

297 ed individuals were matched to 120,373 other antidiabetic users.

298 ay be alleviated and dramatic enhancement of antidiabetic vanadium compounds may result.

299 Studies of antidiabetic vanadium compounds, specifically the organi

300 fruticosa, as structurally new and powerful antidiabetics with unprecedented effects for a dietary m